Brokers Set Expectations for CRSP FY2028 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Brookline Capital Markets reduced their FY2028 earnings per share estimates for shares of CRISPR Therapeutics in a note issued to investors on Monday, November 2nd. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings of $6.73 per share for the year, down from their prior estimate of $6.86. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($4.44) per share. Brookline Capital Markets also issued estimates for CRISPR Therapeutics’ FY2029 earnings at $34.87 EPS and FY2030 earnings at $126.13 EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.06) by ($0.09). The firm had revenue of $12.67 million for the quarter, compared to analysts’ expectations of $14.75 million. CRISPR Therapeutics had a negative net margin of 1,812.07% and a negative return on equity of 24.96%. The company’s revenue was up 1311.1% on a year-over-year basis.

A number of other research firms also recently commented on CRSP. Needham & Company LLC reaffirmed a “buy” rating and set a $82.00 target price on shares of CRISPR Therapeutics in a report on Tuesday. William Blair upgraded shares of CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. UBS Group initiated coverage on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. They set a “neutral” rating and a $52.00 price target for the company. The Goldman Sachs Group reissued a “neutral” rating and set a $55.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Finally, Citizens Jmp restated a “market outperform” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $65.75.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP opened at $49.99 on Wednesday. CRISPR Therapeutics has a 52-week low of $44.12 and a 52-week high of $63.45. The stock has a market cap of $4.83 billion, a price-to-earnings ratio of -10.55 and a beta of 1.92. The company has a quick ratio of 17.85, a current ratio of 17.85 and a debt-to-equity ratio of 0.34. The business has a 50-day moving average price of $53.86 and a 200-day moving average price of $52.85.

Insider Buying and Selling

In other news, Director Simeon George sold 14,514 shares of the firm’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $49.63, for a total transaction of $720,329.82. Following the sale, the director owned 15,486 shares of the company’s stock, valued at $768,570.18. This trade represents a 48.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Samarth Kulkarni sold 47,837 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the transaction, the chief executive officer directly owned 311,899 shares of the company’s stock, valued at approximately $15,526,332.22. This trade represents a 13.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 93,558 shares of company stock worth $4,881,663. 5.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its stake in shares of CRISPR Therapeutics by 175.1% during the 2nd quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after acquiring an additional 296 shares in the last quarter. Compass Financial Management LLC acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter valued at about $25,000. Ameritas Advisory Services LLC acquired a new stake in shares of CRISPR Therapeutics during the 2nd quarter valued at about $56,000. Hollencrest Capital Management grew its position in shares of CRISPR Therapeutics by 249.9% during the 1st quarter. Hollencrest Capital Management now owns 1,312 shares of the company’s stock valued at $62,000 after acquiring an additional 937 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of CRISPR Therapeutics by 92.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,246 shares of the company’s stock valued at $69,000 after acquiring an additional 597 shares during the period. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Key Stories Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: CASGEVY generated $99 million in third-quarter revenue, up 30% from the prior quarter and nearly sixfold year over year. The therapy also gained pediatric approvals in the U.K., the UAE and Bahrain, expanding its potential reach. Company business update and results
• Positive Sentiment: The FDA granted CTX310 regenerative medicine designations, and the company flagged upcoming clinical data presentations for CTX310 and zugo-cel. These developments may provide pipeline catalysts, although they do not guarantee success. Company pipeline update
• Positive Sentiment: Needham reaffirmed its Buy rating and $82 price target, signaling analyst confidence in potential upside. Needham rating
• Neutral Sentiment: CRISPR Therapeutics appointed Siva Sakhamuri as chief technical officer. His manufacturing and technical-operations experience could help support development and commercialization, but the appointment’s financial impact is not yet clear. CTO appointment
• Negative Sentiment: CRSP reported a third-quarter loss of $1.15 per share, wider than the $1.06 consensus loss. Reported revenue of $12.67 million also fell short of the roughly $14.75 million estimate, despite strong year-over-year growth—an earnings miss that may pressure the shares. Quarterly results coverage

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.